Patent intelligence · US
US 10589997
Discrete carbon nanotubes with targeted oxidation levels and stable gel formulations thereof
Discrete carbon nanotubes with targeted oxidation levels and stable gel formulations thereof
Patent details — US 10589997
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 17, 2020
- Expiration
- Mar 12, 2040
- Applicant
- MOLECULAR REBAR DESIGN, LLC
- Claims
- 8
- CPC classes
- A61K, A61K31/455, A61K47/52, A61K47/6923
Quick answer
US 10589997 (Discrete carbon nanotubes with targeted oxidation levels and stable gel formulations thereof) is held by MOLECULAR REBAR DESIGN, LLC. Status: granted. Granted Mar 17, 2020. Expires Mar 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MOLECULAR REBAR DESIGN, LLC
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/455, A61K47/52, A61K47/6923, A61K9/0092
More from MOLECULAR REBAR DESIGN, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12268695
Betulin-containing birch bark extracts and their formulation
granted -
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 12065498
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
US 11998571
Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
granted
Frequently asked questions
What is US patent 10589997?
US 10589997 (Discrete carbon nanotubes with targeted oxidation levels and stable gel formulations thereof) is held by MOLECULAR REBAR DESIGN, LLC. Status: granted. Granted Mar 17, 2020. Expires Mar 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10589997?
MOLECULAR REBAR DESIGN, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.
When does US 10589997 expire?
Our index shows an expiration date of Mar 12, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.